Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating JNJ-63723283, an anti-PD-1 monoclonal antibody, for safety, PK/PD, and clinical activity in participants with advanced cancers; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• JNJ-63723283

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Neoplasms | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING